Related Experiment Video
Updated: Jul 28, 2026
08:18
Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
Published on: September 8, 2021
African Burkitt's lymphoma: a new perspective.
1Viral Oncology Unit, Division of Medicine, Imperial College School of Medicine at St Mary's, Norfolk Place, London W2 1PG, UK.
Summary
High antibody levels to Epstein-Barr virus (EBV) zta protein may predict treatment response in endemic Burkitt's lymphoma (eBL). This finding could aid management in resource-limited settings.
Area of Science:
- Oncology
- Virology
- Immunology
Background:
- Endemic Burkitt's lymphoma (eBL) risk is linked to high Epstein-Barr virus (EBV) antibody titers.
- EBV lytic cycle gene expression in BL correlates with favorable chemotherapy response.
Observation:
- This study explored the correlation between serum antibody response to EBV's zta protein and its gene expression in tumors.
- Investigated the prognostic value of zta antibody serology in eBL patients.
Findings:
- Good correlation observed between serum zta antibodies and tumor zta gene expression in Malawian eBL patients.
- One patient with advanced stage IV eBL and high zta antibody/gene expression showed a positive response to treatment.
- Two EBV-positive cases were diagnosed with rhabdomyosarcoma, a novel association.
Implications:
- Serum antibody response to EBV zta may serve as a predictive marker for chemotherapy responsiveness in eBL.
- Findings suggest potential for improved eBL management strategies in resource-poor regions.
- Identified a potential new association between EBV and rhabdomyosarcoma.
